Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab-beta with Induction Chemotherapy in High-Risk Neuroblastoma
NCT07688252Phase 1Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2032
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Dinutuximab beta in neuroblastoma, sponsored by Chang Gung Memorial Hospital. Primary endpoints: Number of Participants with Unacceptable Toxicities or Toxic Death at 6 months and Clinical Response Rate at 6 months. Started Jul 2026; status: recruiting.
02
Drugs
Dinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07688252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688252.